Sanofi-Synthelabo
New York Division
90 Park Avenue
New York City
New York
10016-1301
United States
Tel: 212-551-4000
Website: http://www.sanofi-synthelabo.us/
About Sanofi-Synthelabo
Sanofi-Synthelabo is a global healthcare company. With annual sales in excess of $5.5 billion and 30,000 employees in more than 100 countries, Sanofi-Synthelabo ranks among the world's top 20 pharmaceutical companies and the top seven pharmaceutical companies in Europe. World headquarters are in Paris, France. U.S. headquarters are in New York City.In the U.S., as in other major markets, the principle area of business of Sanofi-Synthelabo is ethical pharmaceuticals. Core therapeutic areas are cardiovascular disease and thrombosis, diseases of the central nervous system, cancer, and internal medicine.
The foundation of Sanofi-Synthelabo's worldwide growth is a highly regarded Research and Development program, with about 50 compounds under development, half of which are in Phase II and Phase III. Sanofi-Synthelabo has more than 6,000 scientists and R&D support staff in Europe and the U.S.
As we continue intensifying our selling efforts in the U.S., we're planning to add 1,000 more Sales Professionals to a Sales Force that has already doubled in size in just the last two years. In addition, we have a number of Division Manager career opportunities available in select markets throughout the country.
Join us in our fight for health. Healthy sales are sure to follow.
Last Updated 8-29-01
54 articles about Sanofi-Synthelabo
-
Sanofi-Aventis Japan To Merge Sanofi-Synthelabo And Aventis Pharma Japan In January
11/2/2005
-
Sanofi-Aventis Issues Strong Support for Voluntary 'Guiding Principles' on DTC Advertising
8/3/2005
-
Sanofi-Aventis Release: Lovenox(R) Patent Trial Update
6/16/2005
-
Sanofi-Aventis Release: Lantus(R) Add-On To Oral Monotherapy Therapy Showed Improved Glycemic Control In Type 2 Diabetes Patients Compared To Oral Actos Add-On To Oral Therapy
6/13/2005
-
Sanofi-Aventis Release: Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing Of Apidra(R) When Compared To Regular Human Insulin
6/13/2005
-
Docetaxel Lowers Death Rate For Breast Cancer
6/2/2005
-
Sanofi-Aventis Announces Annual General Meeting
6/1/2005
-
WILink Release: 20 Companies To Present At Biotechnology / Healthcare / Pharmaceuticals Forum In NYC On June 15
5/26/2005
-
Sanofi-AventisRelease: Uroxatral(R) (alfuzosin HCl) Study Shows Improvement Up To Two Years In Lower Urinary Tract Symptoms And Sexual Function In Men With Enlarged Prostates
5/26/2005
-
Sanofi-Aventis Release: New Study Demonstrates Clinical Efficacy Of Telithromycin Superior To Standard First-Line Antibiotic Therapy For Treatment Of Mild To Moderate Community-Acquired Pneumonia
5/25/2005
-
Sanofi-Aventis Release: New Data Demonstrate Alvesco(R) (Ciclesonide) Significantly Reduces Oral Corticosteroid Use In Patients With Severe, Persistent Asthma
5/23/2005
-
Sanofi-Aventis (SNY) Release: Taxotere(R) Regimen Demonstrates Significant Survival Benefit In The Treatment Of Advanced Gastric Cancer
5/16/2005
-
The Day In Review: Biotech Ends Winning Streak
4/11/2005
-
The Day In Review: Biotech Marks 5-Year Anniversary Of Nasdaq Bubble Quietly
3/10/2005
-
Sanofi-Aventis Experimental Diet Pill Keeping Pounds Off; Some Snags
3/9/2005
-
Plavix Saves Lives After Big Heart Attacks
3/9/2005
-
Ten Drugs To Watch
2/24/2005
-
Sanofi-Synthelabo Inc. Release: First Pilot Study To Show Benefit Using Hyalgan(R) (Sodium Hyaluronate) In The Treatment Of Osteoarthritis Of The Ankle
2/24/2005
-
Merger Mania Besets Japanese Pharmaceuticals
2/23/2005
-
Sanofi-Aventis World Solidarity Day On Behalf Of South East Asia, January 25, 2005: "Sharing In solidarity"
2/18/2005